The New England Journal of Medicine

Connors, Daniel; Chia, Philip

doi: 10.1056/NEJMicm2415719pmid: 40435467

Insulin-Derived AmyloidosisA 47-year-old man with type 2 diabetes presented with several years of progressive growth of pendulous skin lesions on his lower abdominal wall where he had repeatedly injected insulin.

Servattalab, Sarah; Grenier, Pierre-Olivier

doi: 10.1056/NEJMicm2414170pmid: 40421726

Tufted Angioma with Kasabach–Merritt PhenomenonA full-term baby boy was evaluated at a quaternary care hospital for a large, violaceous, firm, hypertrichotic plaque on the right side of the back. Laboratory studies showed thrombocytopenia and low fibrinogen and elevated d-dimer levels.

Li, Suellen; Burke, Alison E.; Koscal, Natalie; Solomon, Caren G.

doi: 10.1056/NEJMp2414536pmid: 40435464

A Burning QuestionThis Double Take video explores the differential diagnosis for progressive dyspnea and cough and highlights the importance of taking a thorough history.

doi: 10.1056/NEJMc2503896pmid: 40435474

To the Editor: In the comparison of colchicine with placebo in the CLEAR trial, Jolly et al. (Feb. 13 issue)1 found that among patients who had an acute myocardial infarction, treatment with colchicine, when started within 72 hours after the index percutaneous coronary intervention, did not reduce the incidence of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization (the composite primary outcome). Their findings differ from those of the Colchicine Cardiovascular Outcomes Trial (COLCOT), in which colchicine led to a significantly lower risk of a composite primary end-point event than placebo in patients who underwent . . .

Sachs, Rachel E.; Sharfstein, Joshua M.; Zettler, Patricia J.

doi: 10.1056/NEJMp2504926pmid: 40334193

Judicial Invalidation of the FDA’s LDT RuleRecently, a federal judge struck down an FDA rule on laboratory-developed tests. If this invalidation stands, it will have consequences for clinical care and the FDA’s authority over medical devices.

Tossas, Katherine Y.; Owens, Bianca D.; Hong, Susan; Quillin, John; Adkins, Stephen; Thomson, Maria; Winn, Robert A.

doi: 10.1056/NEJMp2415951pmid: 40421729

The GINA GapNative Americans who receive care from the Indian Health Service aren’t covered by the federal law that bans discrimination based on genetic makeup, which could perpetuate health disparities.

Pisetsky, David

doi: 10.1056/NEJMp2416194pmid: 40421741

The Meaning of GoodbyeWhen a physician’s wife has Alzheimer’s disease — the worst disease for the patient’s partner, according to their doctor — he must grapple with effects more challenging than memory loss.

Song, Zirui; Zhu, Jane M.

doi: 10.1056/NEJMp2501717pmid: 40421728

Primary Care and the Free MarketPrimary care physicians have been leaving traditional practices for concierge and direct primary care practices, in which patients are offered personalized and more accessible primary care in exchange for membership fees.

Ganapathiraju, Pavan V.; Traylor, Rebecca J.

doi: 10.1056/NEJMp2504204pmid: 40421733

Undermining a PACTA 2022 law that expanded treatment for veterans with certain conditions was long overdue. But delivering on its promise depends on VA clinicians and support staff, whose jobs are now at risk.

doi: 10.1056/NEJMtwj250529pmid: N/A